Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.

Autor:	Casale TB; University of South Florida, Tampa, Fla., Luskin AT; HealthyAirways, Madison, Wis., Busse W; University of Wisconsin School of Medicine and Public Health, Madison, Wis., Zeiger RS; Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, Calif., Trzaskoma B; Genentech, Inc, South San Francisco, Calif., Yang M; Genentech, Inc, South San Francisco, Calif., Griffin NM; Genentech, Inc, South San Francisco, Calif. Electronic address: noelle.griffin@gmail.com., Chipps BE; Capital Allergy and Respiratory Disease Center, Sacramento, Calif.
Jazyk:	angličtina
Zdroj:	The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2019 Jan; Vol. 7 (1), pp. 156-164.e1. Date of Electronic Publication: 2018 May 22.
DOI:	10.1016/j.jaip.2018.04.043
Abstrakt:	Background: Omalizumab has demonstrated efficacy in clinical trials of patients with asthma, but real-world data are needed. Objective: To assess outcomes after omalizumab initiation in patients with asthma in a real-world setting. Methods: Patients aged 12 years and older with allergic asthma who were candidates for omalizumab on the basis of physician-assessed need were enrolled in a US-based, prospective, single-arm, 48-week multicenter study, the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab. Monthly assessments included exacerbations, health care utilization, asthma control test (ACT), and adverse events. At baseline, 6 months, and end of study, biomarkers (blood eosinophils and fractional exhaled nitric oxide) were collected and spirometry performed. Results: Of 806 enrollees, 801 (99.4%) received omalizumab and 622 (77.2%) completed the study. The exacerbation rate significantly improved from a mean of 3.00 ± 3.28 in the 12 months before baseline to 0.78 ± 1.37 through month 12 (P < .001) and was similar in adults and adolescents; there was a reduction of 81.9% in the percentage of patients with 1 or more hospitalizations. Lung function remained generally unchanged. A mean improvement of 4.4 ± 4.9 in ACT scores was observed. Eighty-seven percent of patients were responders on the basis of clinical improvement in exacerbations, lung function, or ACT scores. Baseline biomarker status was associated with ACT scores and lung function improvement, but the magnitude of this improvement was not clinically relevant. No new safety signals emerged. Conclusions: Omalizumab initiation in patients with asthma resulted in improved exacerbation rates, reduced hospitalizations, and improved ACT scores compared with pretreatment values, regardless of biomarker status. (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu